SOM Biotech and Vall d’Hebron successfully complete a clinical trial in patients with TTR amyloidosis Blog Post

SOM Biotech and the Vall d’Hebron Research Institute (VHIR) have successfully completed a Phase IIa proof-of-concept clinical trial in humans to evaluate the efficacy and safety of an innovative oral therapy for transthyretin amyloidosis (TTA), a rare disease that affects the peripheral nervous system and heart. To carry out this trial, the hospital and the Catalan biotech, with headquarters at the Barcelona Science Park (PCB), signed an risk-sharing agreement under (RSA) which they jointly assumed the risks and economic returns of the project.

 

A scientific study outlines the evolution of genes involved in selenoprotein synthesis Blog Post

An international study has been highlighted on the cover of the prestigious journal Genome Research. It illustrates the evolution of selenophosphate synthetase genes —involved in selenoprotein synthesis— in prokaryotic and eukaryotic organisms. Montserrat Corominas and Florenci Serras, professors in the Department of Genetics and researchers at the Institute of Biomedicine of the University of Barcelona (IBUB) at PCB, participate in the study together with the scientific team led by Roderic Guigó, expert at the Centre for Genomic Regulation (CRG-UPF).

 

New computational approach to predicting adverse drug reactions with higher confidence Blog Post

A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods. This improved ability to foresee the possible adverse effects of drugs may entail saving many lives in the future. The study that is being conducted by researchers from IMIM (Hospital del Mar Medical Research Institute), Pompeu Fabra University (UPF), and the company Chemotargets at PCB, within the framework of the European eTOX project, was chosen for the cover of the journal Chemical Research in Toxicology.

 

New Trojan horses to conquer the brain Blog Post

20 pioneering scientists present their latest research on the barrier and the breakthroughs in therapeutic shuttle transporters that target the brain in the ‘Blood-Brain-Barrier’ Barcelona Biomed Conference, an event organised by IRB Barcelona with the University of Tohoku (Japó) and supported by the BBVA Foundation. One of the latest results is a shuttle based on bee venom developed by Ernest Giralt’s Lab from IRB Barcelona at PCB. The conference starts today at the Institut d’Estudis Catalans in Barcelona and ends on Wednesday 4th November.

 

A big step towards understanding the electric properties of the cell Blog Post

Having measured the electric polarizability of DNA – a fundamental property that directly influences its biological functions – for the first time ever last year, researchers from IBEC at PCB has made a further breakthrough in the understanding of the dielectric properties of cell constituents by measuring the electric polarizability of the main components of the cell membrane – namely lipids, sterols and proteins – with a spatial resolution down to 50nm.

 

PCB hosts a ‘Lessons Learned’ session on investment in R & D and tax administration Blog Post

Thursday, the 22 of October, Barcelona Science Park (PCB) hosted the 8th session of ‘Lessons Learned’ series: ‘Biofiscalitat: els incentius per a la ciència‘, an initiative of CataloniaBio and Biocat to foster knowledge and networking among professionals in the field of life sciences. On this occasion, the aim of the event was to gain further insight and analyze the tools to overcome the regulations and red tape governing the taxation regimen of biotechnological and biomedical companies which hamper R & D.

 

Mind the byte concludes the biggest round of biotech crowdequity in Spain Blog Post

In just 43 days, bioinformatics company Mind the Byte, which specializes in products and services for computational drug design and is located in the Barcelona Scientific Park (PCB), has concluded an investment round totalling €234,310 through the crowdequity platform (for investment crowdfunding) Crowdcube. This figure represents not only more than double the funding target set by the company (234%), but it is also the largest round of crowdequity achieved in the biotech industry in Spain, with 115 private investors. The average investment amount was €2,037, with a maximum investment of €80,000.

 

Renewal of IRB Barcelona’s ‘Severo Ochoa’ Accreditation of Excellence Blog Post

This morning the Secretary of State for I+D+I has announced that the first eight ‘Severo Ochoa’ Centres of Excellence‘ ─whose strategic research plans for the period 2016-2019 have been positively evaluated─ have been awarded this distinction again, which has won them  a grant of 1 million euros a year for a further four years. One of these centers is the Institute for Biomedical Research (IRB Barcelona), which received the news during its 10th year anniversary institutional event at the Centre de Cultura Contemporània de Barcelona (CCCB). Last March, the Institute of Bioengineering of Catalonia (IBEC) was granted the Severo Ochoa accreditation, which means that Barcelona Science Park (PCB) now is home to two of the centers that have been presented with this distinction.

 

A study applies iPSC technology to Sanfilippo syndrome research Blog Post

Sanfilippo type c syndrome is a lysosomal storage disorder caused by mutations in the HGSNAT gene that leads to progressive neurodegeneration. A study, which has just been published in the journal Stem Cell Reports, has generated patient-specific induced pluripotent stem cells (iPSC) which can contribute to know better disease’s pathological mechanisms and design new therapeutic options. A group of researchers from the Institute of Biomedicine of the University of Barcelona (IBUB) and Institute for Bioengineering of Catalonia (IBEC) at PCB has participated in the study.